CD
5
0
0
3
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
0.0%
0 terminated out of 5 trials
100.0%
+13.5% vs benchmark
20%
1 trials in Phase 3/4
33%
1 of 3 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (5)
Changing the coUrse of cRohn's Disease With an Early Use of Adalimumab
Is the Endoscopic Remission Evaluation, Using the CREDO 1 Index / Score in CD Patients in Clinical Remission at Baseline, Predictive of Sustained Clinical Remission Using a 2-year Follow up
Crohn's Disease Endoscopic REmission Definition in an Objective Way
Predictive Factors of ANTI-TNF Response in Luminal Crohn's Disease Complicated by Abscess
Bacteriotherapy in Pediatric Inflammatory Bowel Disease